Spectrum

[키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant adverse event age Analysis AS03 assigned baseline candidate vaccine caused conducted coronavirus coronavirus disease Coronavirus disease 2019 CoVLP CoVLP+AS03 determine disease dose effective Efficacy Factor FIVE incidence injection intention-to-treat intention-to-treat population Intramuscular injection Local median age Median viral load Medicago Mild moderate occurred participant Participants participated Particle performed Phase 3 Placebo placebo group placebo-controlled trial plant plants polymerase post-hoc analysis prefusion produced Randomized receive recombinant respiratory Safety SARS-CoV-2 sequenced Sequencing seronegative severe acute respiratory syndrome Coronavirus Severe case Spectrum spike glycoprotein symptomatic symptomatic COVID-19 symptomatic infection System systemic adverse event systemic adverse events the median the placebo group the vaccine Trial two group two groups Vaccine vaccine efficacy vaccine group variant variants Viral Viral load viral sample Volunteer
[DOI] 10.1056/NEJMoa2201300 PMC 바로가기 [Article Type] Clinical Trial